Press Releases Almirall, S.A.

Equities

ALM

ES0157097017

Market Closed - BME Other stock markets 09:05:09 21/06/2024 pm IST			5-day change	1st Jan Change
9.62 ^EUR	-2.19%		-2.38%	+14.18%

10/06	Almirall: extension of indication in actinic keratosis	CF
10/06	Almirall’s Skin Disease Drug Gets US FDA Nod for Larger Treatment Area	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

FDA Approves Almirall’s Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis on Expanded Area of Face or Scalp up to 100 cm2	10/06	BU
Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio	13/05	BU
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	13/03	BU
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology	19/02	BU
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business	19/02	BU
Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases	21/12	BU
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology	12/12	BU
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis	17/11	BU
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases	14/11	BU
Almirall’s Nine-month 2023 Results	09/11	BU
Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years	20/23/20	BU
Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1	13/23/13	BU
Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis	11/23/11	BU
Centrient Pharmaceuticals joins Almirall’s growing innovation hub in Barcelona	10/23/10	BU
EBGLYSS® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis	15/23/15	BU
Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business	24/23/24	BU
Almirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis	07/23/07	BU
Almirall launches Nina, the first series to highlight the major impact of psoriasis on patient’s wellbeing	20/23/20	BU
Almirall announces the pricing and closing of its €200mm non pre-emptive share capital increase	13/23/13	BU
Almirall Announces the Launch of a €200mm Non Pre-Emptive Share Capital Increase	12/23/12	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Almirall, S.A.

Equities

ALM

ES0157097017

Press Releases

Filters